Mounjaro, Zepbound shortage eases as supplies of weight loss drug rebound [USA TODAY]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: USA TODAY
Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, has been in short supply since 2022 amid skyrocketing demand. The medication is part of the blockbuster category of weight-loss and diabetes drugs called glucagon-like peptide 1, or GLP-1. Novo Nordisk's diabetes drug Ozempic isn't in short supply. However, shortages remain for the low-dose of the weight-loss drug Wegovy, the The FDA confirmed with Eli Lilly that it has enough manufacturing capacity for tirzepatide to meet current and projected demand. However, the FDA said some patients may experience "intermittent localized supply disruptions" as the drug moves from distributors to pharmacies. The FDA's notice means companies that make cheaper copies of tirzepatide will face new restrictions on marketing those medications. The FDA allows compounding pharmacies to sell copies of drugs when the medications are in short supply. But compounding pharmacies face stiffer restrictions when a dru
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- What end of Eli Lilly's weight-loss drug shortage means for the competition [Yahoo! Finance Canada]Yahoo! Finance Canada
- Eli Lilly's Mounjaro, Zepbound removed from FDA's shortage list [Yahoo! Finance Canada]Yahoo! Finance Canada
- What end of Eli Lilly's weight-loss drug shortage means for the competition [Yahoo! Finance]Yahoo! Finance
- England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access [Yahoo! Finance]Yahoo! Finance
- NHS proposes phased launch for Eli Lilly's Mounjaro [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 8/8/24 - Beat
LLY
Sec Filings
- 9/18/24 - Form 3
- 9/17/24 - Form 4
- 9/17/24 - Form 4
- LLY's page on the SEC website